FNZ

FNZ is a synthetic opioid belonging to the nitazene class, a group of compounds originally developed in the 1950s but largely shelved due to extreme potency. Re-evaluated by researchers at the National Institute on Drug Abuse (NIDA) and the National Institutes of Health (NIH), FNZ acts as a potent mu-opioid receptor agonist. In preclinical studies, it was primarily utilized as a chemical probe for positron emission tomography (PET) imaging to track brain penetration and kinetics in real-time. While FNZ provides effective analgesia, it is associated with significant safety risks typical of potent opioids, including respiratory depression and a high potential for addiction. It is the metabolic parent of DFNZ, a mu-opioid receptor superagonist that exhibits a significantly improved safety profile with minimal respiratory or addictive liabilities.